IDiyas

For the Inventor, By the Inventor

Raleigh, NC, United States of America

Andrew Spaltenstein

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 7.0

ph-index = 5

Forward Citations = 82(Granted Patents)


Company Filing History:

goldMedal13 out of 1,149 
 
Vertex Pharmaceuticals, Inc.
 patents
silverMedal2 out of 40 
 
Viiv Healthcare Company
 patents
bronzeMedal2 out of 60 
 
Janssen Sciences Ireland Unlimited Company
 patents
where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...
Loading Chart...
15 patents (USPTO):
1. 12178815 - Regimens for treating HIV infections and aids (2024-12-31),
2. 11564921 - Regimens for treating HIV infections and AIDS (2023-01-31),
3. 8455497 - Inhibitors of aspartyl protease (2013-06-04),
4. 7919523 - Inhibitors of aspartyl protease (2011-04-05),
5. 7592368 - Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors (2009-09-22),
6. 7442718 - Inhibitors of aspartyl protease (2008-10-28),
7. 7419967 - Sulfonamide inhibitors of aspartyl protease (2008-09-02),
8. 6878728 - Inhibitors of aspartyl protease (2005-04-12),
9. 6838474 - Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors (2005-01-04),
10. 6617350 - Inhibitors of aspartyl protease (2003-09-09),
11. 6613743 - Sulfonamide inhibitors of aspartyl protease (2003-09-02),
12. 6559137 - Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors (2003-05-06),
13. 6436989 - Prodrugs of aspartyl protease inhibitors (2002-08-20),
14. 6319946 - Inhibitors of aspartyl protease (2001-11-20),
15. 5945413 - Aspartyl protease inhibitors (1999-08-31),

Title: The Innovative Contributions of Andrew Spaltenstein

Introduction

Andrew Spaltenstein is a notable inventor based in Raleigh, NC, who has made significant contributions to the field of medicine, particularly in the treatment of HIV infections and AIDS. With a total of 15 patents to his name, Spaltenstein's work reflects a commitment to advancing healthcare solutions.

Latest Patents

Among his latest patents is a method for treating HIV that involves intramuscular administration of a combination of cabotegravir and rilpivirine. This innovative approach allows for administration once every four weeks or less frequently, providing an option to discontinue the first oral anti-retroviral regimen. This method represents a significant advancement in the management of HIV infections.

Career Highlights

Throughout his career, Andrew Spaltenstein has worked with prominent companies in the pharmaceutical industry, including Vertex Pharmaceuticals, Inc. and ViiV Healthcare Company. His experience in these organizations has contributed to his expertise in developing effective treatment regimens for HIV.

Collaborations

Some of his notable coworkers include Michael Robin Hale and Eric Steven Furfine, who have collaborated with him on various projects aimed at improving patient outcomes in HIV treatment.

Conclusion

Andrew Spaltenstein's innovative work and dedication to advancing medical treatments have made a significant impact in the field of healthcare. His contributions continue to influence the way HIV infections are managed, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…